Artificial platelet lysate and use thereof
A novel artificial platelet lysate, enriched with specific growth factors, addresses the variability and safety issues of existing cell culture media, ensuring stable cell growth and safety in a controlled process.
Patent Information
- Application Number
- PCT/KR2026/096431
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2026-04-24
- Filing Date
- 2026-04-29
- Publication Date
- 2026-11-12
AI Technical Summary
Existing cell culture media, such as Fetal Bovine Serum (FBS) and blood-derived platelet lysate, face issues like batch variability, ethical concerns, import restrictions, and quality control challenges, while human-derived platelet lysate has limited availability and risks of infectious agents.
A novel artificial platelet lysate is developed, comprising specific growth factors (bFGF, SCF-R, PDGF-AA, PDGF-BB, EGF, GDF-15, IGFBP-2, TGF-β, and TIMP-1, produced through a controlled process involving pluripotent stem cell culture and megakaryocyte differentiation, to create a stable and safe cell culture medium.
The artificial platelet lysate provides consistent cell growth promotion and high safety, overcoming the limitations of animal-derived and human-derived alternatives by maintaining cell survival and proliferation effectively.
Smart Images

Figure KR2026096431_12112026_PF_FP_ABST
Abstract
Description
Artificial platelet lysate and uses thereof
[0001] The present invention relates to an artificial platelet lysate and a culture medium composition containing the same.
[0002] Cell culture is a method of growing cells under controlled conditions outside of their natural environment and is an essential technology for biotechnology, genetic engineering, pharmaceutical research, and new drug development. To enable cells to divide and proliferate in an environment similar to that in vivo, appropriate culture media and cell growth-promoting factors must be provided. Currently, in the field of cell culture, Fetal Bovine Serum (FBS), which contains various growth factors and has excellent cell growth-promoting effects, is widely used.
[0003] However, FBS is a complex substance with unclear composition, posing problems such as significant batch-to-batch variability and difficulties in quality control. Furthermore, ethical and safety issues regarding the animal-derived nature of the material are continuously being raised. Additionally, FBS produced in specific regions is subject to import restrictions or limitations on its use in the production of clinical drugs; as the domestic market relies heavily on imports, supply instability may arise.
[0004] To address these issues, blood-derived platelet lysate has been proposed as a substitute for FBS and is utilized as an additive in cell culture media due to its excellent cell growth-promoting ability. However, blood-derived platelet lysate exhibits significant variation between production batches due to differences in platelet status depending on the donor's health condition or the time of collection, and poses a risk of potential exposure to infectious agents. Additionally, because the amount of platelets obtainable from a single individual is limited, it is often manufactured by pooling blood from multiple donors, which presents a problem in that consistent quality control is difficult.
[0005] Therefore, there is a need to develop a new cell culture composition that can provide a cell growth-promoting effect while overcoming the limitations of animal-derived fetal bovine serum and human blood-derived platelet lysates.
[0006] The present invention aims to provide a novel artificial platelet lysate.
[0007] In addition, the present invention aims to provide a culture medium composition that has excellent cell growth-promoting ability and high safety.
[0008] 1. An artificial platelet lysate comprising 0.1 to 0.3 ng / ml bFGF, 1 to 5 ng / ml SCF-R, 1 to 3 ng / ml PDGF-AA, 10 to 20 pg / ml EGF, 0.1 to 0.2 ng / ml GDF-15, and 10 to 40 ng / ml IGFBP-2.
[0009] 2. An artificial platelet lysate comprising, in addition to 0.5 to 1 ng / ml of PDGF-BB and 25 to 45 ng / ml of TIMP-1 in the above 1.
[0010] 3. In the above 1, the artificial platelet lysate comprises: (S1) a step of culturing pluripotent stem cells to obtain a culture medium containing hematopoietic stem cells; (S2) among the cells contained in the culture medium, CD34 + An artificial platelet lysate prepared by a method comprising the steps of: (S3) obtaining a suspension cell population from the culture medium when the number of cells is at least 90% of the total number of cells; (S4) differentiating the suspension cell population into megakaryocytes in a first medium; (S5) culturing and maturing the megakaryocytes in a second medium containing TPO and SCF; (S6) isolating and purifying the culture of (S4) to obtain platelets; and (S6) crushing the platelets.
[0011] 4. In the above 3, the step (S1) comprises: (S1a) culturing the pluripotent stem cells in a third medium containing a GSK3 inhibitor; (S1b) culturing the cells cultured in the third medium in a fourth medium containing vascular endothelial growth factor and basic fibroblast growth factor; and (S1c) culturing the cells cultured in the fourth medium in a fifth medium containing vascular endothelial growth factor; basic fibroblast growth factor; and a transforming growth factor beta signaling inhibitor, for an artificial platelet lysate.
[0012] 5. In the above 3, the method comprises (S0) culturing the pluripotent stem cells at a density of 5,000 to 8,500 cells / cm² on the bottom of a culture vessel. 2 Artificial platelet lysate including an additional seeding step.
[0013] 6. In the above 3, the first medium is an artificial platelet lysate containing TPO and SCF and not containing interleukin-3 and interleukin-6.
[0014] 7. In the above 6, among the cells included in the culture medium in (S2), CD34 + The cell count is at least 90% of the total cell count, and CD41a + The cell count is 50% to 80% of the total cell count, and CD42b + An artificial platelet lysate obtained from the culture medium when the number of cells is 40% to 60% of the total number of cells.
[0015] 8. In the above 3, the second medium further comprises an artificial platelet lysate comprising heparin sodium and a ROCK inhibitor.
[0016] 9. In 3 above, megakaryocytes are 1.0 × 10⁶ in a culture vessel with baffles formed on the bottom surface or in a stirred bioreactor. 5 Up to 2×10 5 cells / cm 2 Artificial platelet lysate that is injected and cultured.
[0017] 10. A culture medium composition comprising an artificial platelet lysate of any one of claims 1 to 9 above.
[0018] 11. A culture medium composition comprising, in addition to any one additive selected from the group consisting of serum, insulin-transferrin-selenium supplement, glucocorticoid hormone, and plant-derived protein hydrolysate, the above 10.
[0019]
[0020] 12. A culture medium composition according to 11, wherein the glucocorticoid hormone is one or more selected from the group consisting of hydrocortisone, dexamethasone, prednisolone, corticosterone, methylprednisolone, and betamethasone.
[0021] 13. A culture medium composition according to 11, wherein the plant-derived protein hydrolysate is a hydrolysate of a protein derived from any one plant selected from the group consisting of soybeans, wheat, peas, rice, potatoes, and corn.
[0022] 14. A culture medium composition according to 10, wherein the artificial platelet lysate is included at a concentration of 1 μg / mL to 1000 μg / mL.
[0023] 15. A culture medium composition used for culturing any one or more selected from the group consisting of immune cells, stem cells, and stromal cells, in accordance with 10 above.
[0024] The present invention provides an artificial platelet lysate containing various growth factors.
[0025] The artificial platelet lysate of the present invention contains various types of growth factors at high concentrations compared to human-derived platelets, and accordingly can provide an environment favorable for maintaining cell survival and proliferation.
[0026] The artificial platelet lysate of the present invention can effectively promote cell growth and proliferation by including various physiologically active factors involved in cell growth.
[0027] In addition, the culture medium composition of the present invention can stably maintain cell survival and promote cell proliferation by including the artificial platelet lysate as an active ingredient.
[0028] The culture medium composition of the present invention can effectively promote cell growth and proliferation during the cell culture process.
[0029] Figure 1a is an example of the culture process of human induced pluripotent stem cells.
[0030] Figure 1b shows photographs of the culture medium on days 1 and 3 for obtaining human induced pluripotent stem cells.
[0031] FIG. 2a is an example of a process for obtaining a culture medium containing hematopoietic stem cells by culturing the obtained human induced pluripotent stem cells.
[0032] Figure 2b is a photograph of the culture medium on days 2, 5, and 9 of culture to obtain the culture medium containing hematopoietic stem cells.
[0033] Figure 3 is a photograph of the culture medium containing the suspension cell population of Example 1.
[0034] Figure 4 is an example of a process for differentiating and maturing a floating cell population into megakaryocytes.
[0035] Figures 5a and 5b are the results of comparing the expression ratios of surface markers (CD34, CD45, CD41a, and CD42b) before and after freezing of the suspension cell population of Example 1.
[0036] Figure 6 is the result of confirming the number of chromosomes of a megakaryocyte obtained in step (S3) of Example 1.
[0037] Figure 7 is a micrograph of a megakaryocyte finally obtained in step (S4) of Example 1.
[0038] Figure 8 is the result of confirming the number of chromosomes of the megakaryocyte finally obtained in step (S4) of Example 1.
[0039] Figure 9 is a micrograph of a platelet from Example 1.
[0040] Figure 10 is a graph comparing the content of major growth factors in Example 1, Comparative Example 2, and human blood-derived platelets.
[0041] Figures 11a and 11b show the results of analyzing the growth factors of the platelet lysate of Example 1 and a commercially available human blood-derived platelet lysate.
[0042] Figure 12 is a schematic diagram of the platelet purification process of Example 1.
[0043] Figures 13a to 13c show the results of a comparison of cell growth-promoting ability according to the platelet lysate of Example 1, human blood-derived platelet lysate, or FBS treatment.
[0044] Figures 14a and 14b are photographs showing the results of treating human skin fibroblasts with the platelet lysate of Example 1, ITS-X, FBS, or a combination thereof.
[0045] Figure 15 shows the result of counting the number of cells after treating human skin fibroblasts with the platelet lysate of Example 1, ITS-X, FBS, or a combination thereof.
[0046] Figures 16 and 17 show the results of the analysis of changes in the area of the damaged site after treating a human skin fibroblast wound model with the platelet lysate and / or FBS of Example 1.
[0047] Figures 18 and 19 show the results of observing changes in cell numbers after treating human skin fibroblasts with a combination of FBS, ITS, hydrocortisone, or the platelet lysate of Example 1.
[0048] Figures 20a, 20b, and 21 are the results of the analysis of changes in cell number after treatment with the combination of platelet lysate of Example 1 and various medium additives.
[0049] The present invention provides an artificial platelet lysate and uses thereof.
[0050] The present invention provides an artificial lysate in which the concentration of any one growth factor selected from the group consisting of PDGF-AA, PDGF-BB, EGF, TGF-β, bFGF and VEGF is increased compared to a human-derived platelet lysate.
[0051] The artificial platelet lysate of the present invention contains various growth factors, and the concentration of growth factors is higher than that of human-derived platelet lysate.
[0052] The present invention provides an artificial platelet lysate comprising 0.1 to 0.3 ng / ml of bFGF, 1 to 5 ng / ml of SCF-R, 1 to 3 ng / ml of PDGF-AA, 10 to 20 pg / ml of EGF, 0.1 to 0.2 ng / ml of GDF-15, and 10 to 40 ng / ml of IGFBP-2.
[0053] The artificial platelet lysate of the present invention is prepared according to a predetermined method.
[0054] The artificial platelet lysate of the present invention may be prepared by a method comprising: (S1) culturing pluripotent stem cells to obtain a culture medium containing hematopoietic stem cells; (S2) obtaining a floating cell population from the culture medium when the number of CD34+ cells among the cells contained in the culture medium is at least 90% of the total number of cells; (S3) differentiating the floating cell population into megakaryocytes in a first medium; (S4) culturing the megakaryocytes in a second medium containing TPO and SCF to mature them; (S5) isolating and purifying the culture of (S4) to obtain platelets; and (S6) crushing the platelets.
[0055] The method for producing platelets according to the present invention (S0) places pluripotent stem cells at a rate of 2,000 to 20,000 cells / cm² on the bottom of a culture vessel. 2It may include additional seeding steps.
[0056] The platelet manufacturing process from (S0) to (S6) is described below.
[0057]
[0058] (S0) Step
[0059] (S0) is pluripotent stem cells at a density of 2,000 to 20,000 cells / cm² on the bottom of the culture vessel. 2 This is the seeding stage.
[0060] Pluripotent stem cells include induced pluripotent stem cells (iPSCs) or embryonic stem cells (ESCs).
[0061] Induced pluripotent stem cells (iPSCs) refer to differentiated cells that originally lacked pluripotency but have acquired this ability through an artificial dedifferentiation process.
[0062] Induced pluripotent stem cells (iPSCs) may be derived from individuals selected from a group including humans, non-human primates, rodents (mice, rats), ungulates (cattle, sheep, etc.), dogs (pet and wild dogs), cats (pet and wild cats such as lions, tigers, and cheetahs), rabbits, hamsters, goats, elephants, pandas (including giant pandas), pigs, raccoons, horses, zebras, and marine mammals (dolphins, whales, etc.).
[0063] Induced pluripotent stem cells can be human induced pluripotent stem cells (hiPSCs).
[0064] Induced pluripotent stem cells may be generated using mouse and / or human cells. For example, induced pluripotent stem cells may be generated using embryonic, fetal, neonatal, and adult tissues.
[0065] Induced pluripotent stem cells may utilize any somatic cell of substantially any developmental stage as a starting point. The somatic cell may be derived from, but is not limited to, embryos, fetuses, newborns, children, or adult donors. The somatic cell may be, but is not limited to, fibroblasts, such as skin fibroblasts obtained from a skin sample or biopsy, synoviocytes from synovial tissue, ball cells, or lung fibroblasts.
[0066] Pluripotent stem cells are seeded onto the bottom of the culture vessel and then cultured in attachment.
[0067] The bioreactor may be used without restriction as long as it is used for cell culture in the industry. For example, it may be large, medium, or small bioreactors. It may also be cell culture flasks such as the T25, T75, T175, or T225.
[0068] It is desirable to seed pluripotent stem cells at a density of 5,000 to 8,500 cells / cm² in terms of promoting cell growth and differentiation. Pluripotent stem cells must be seeded at an appropriate density on the bottom of the culture vessel so that they can be converted into suspension cells after sufficient culture and differentiation, and the number of cells expressing CD34 among the cells in the culture medium containing hematopoietic stem cells can reach 90% of the total number of cells, thereby ensuring the quality of the platelets produced.
[0069] When pluripotent stem cells are seeded at a low density of 5,000 cells / cm² or less on the bottom of the culture medium, insufficient cell-to-cell interaction occurs, resulting in poor growth and early differentiation, and consequently, insufficient conversion to floating cells may occur. Conversely, when pluripotent stem cells are seeded at a high density exceeding 8,500 cells / cm² on the bottom of the culture medium, the relative concentration of factors added to the culture medium becomes insufficient, preventing smooth cell-to-cell signaling, and consequently, differentiation may not proceed efficiently.
[0070] Pluripotent stem cells can be seeded at 5,000 to 8,500 cells / cm², for example, 5,000 to 8,500 cells / cm², 5,000 to 8,300 cells / cm², 5,000 to 8,000 cells / cm², 5,000 to 7,800 cells / cm², 5,000 to 7,500 cells / cm², 5,000 to 7,200 cells / cm², 5,000 to 7,000 cells / cm², 5,100 to 7,000 cells / cm², 5,100 to 6,800 cells / cm², 5,100 to 6,600 cells / cm², 5,100 to 6,400 cells / cm², 5,100 to 6,300 It may be cells / cm², 5,200 to 6,100 cells / cm², 5,000 to 6,000 cells / cm², 5,300 to 6,000 cells / cm², 5,100 to 6,000 cells / cm², 5,100 to 5,900 cells / cm², 5,200 to 5,800 cells / cm², 5,300 to 5,700 cells / cm², or 5,400 to 5,600 cells / cm².
[0071]
[0072] (S1) Step
[0073] Step (S1) is a step of culturing pluripotent stem cells to obtain a culture medium containing hematopoietic stem cells. This step is a step of culturing the pluripotent stem cells seeded in Step (S0) to obtain a floating cell population capable of differentiating into megakaryocytes.
[0074] (S1) Step may be configured to include the following detailed steps:
[0075] (S1a) A step of culturing pluripotent stem cells in a third medium containing a GSK3 (Glycogen Synthase Kinase 3) inhibitor;
[0076] (S1b) A step of culturing cells cultured in a third medium in a fourth medium containing vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF); and
[0077] (S1c) A step of culturing cells cultured in a fourth medium in a fifth medium containing vascular endothelial growth factor; basic fibroblast growth factor; and a transforming growth factor beta signaling inhibitor.
[0078] The third, fourth, and fifth media used in this step are media having different compositions and purposes.
[0079] The third medium contains at least a GSK3 inhibitor. The GSK3 inhibitor may be, but is not limited to, CHIR99021, BIO(6-bromoindirubin-30-oxime), SB216763, CHIR-98014, CT98014, CT98023, CT99021, TWS119, SB41528, AR-A014418, AZD-1080, Alsterpaullone, Cazpaullone, or Kenpaullone. CHIR99021 is a GSK3 inhibitor and a Wnt signaling agonist, and may be represented as aminopyrimidine.
[0080] The GSK3 inhibitor (e.g., CHIR99021) is not limited to a specific concentration as long as it is in an amount sufficient to culture pluripotent stem cells. The GSK3 inhibitor may be included in the third medium at concentrations such as 2 to 10 μM, 2.5 to 9.5 μM, 3 to 9 μM, 3.5 to 8.5 μM, 4 to 8 μM, 4.5 to 7.5 μM, 5 to 7 μM, 5.5 to 6.5 μM, or 6 μM.
[0081] The third medium is a basal medium. The third medium may include RPMI1640 medium or other types of basal medium. The third medium may further include an antioxidant and / or B-27 along with the basal medium.
[0082] Antioxidants include 6-hydroxymelatonin, acetyl-L-carnitine (ALCAR), alpha-lipoic acid (ALA), ascorbic acid (e.g., AA2P (L-Ascorbic acid 2-phosphate), AA2G (L-Ascorbic acid 2-glucoside)), carotenoids (vitamin A), curcumin, edaravone, polyphenols, glutathione, hydroxytyrosol, L-carnitine, radostigil, melatonin, mofegiline, and N-acetylcysteine (NAC). It can be selected from the group consisting of N-acetylserotonin (N-Acetylserotonin, NAS), oleocanthal, oleuropein, rasagiline, resveratrol, selegiline, selenium, tocopherols (vitamin E), tocotrienols, tyrosol, ubiquinone (coenzyme Q), and uric acid.
[0083] The fourth medium is a growth medium. The fourth medium contains at least growth factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF). The fourth medium may further contain other growth factors to culture pluripotent stem cells.
[0084] Vascular Endothelial Growth Factor (VEGF) is a member of the Epidermal Growth Factor Receptor (EGFR / ErbB). VEGF plays an essential role in regulating cell proliferation and differentiation, and induces apoptosis, survival, or cell proliferation by causing the activation of various forms of signaling pathways. Vascular Endothelial Growth Factor includes, for example, VEGF from humans and non-human animals (such as mice).
[0085] Vascular endothelial growth factor is included at a concentration that allows for the appropriate culture of pluripotent stem cells. Vascular endothelial growth factor may be included in the fourth medium at a concentration of, for example, 5 to 95 ng / ml, 10 to 90 ng / ml, 15 to 85 ng / ml, 20 to 80 ng / ml, 25 to 75 ng / ml, 30 to 70 ng / ml, 35 to 65 ng / ml, 40 to 60 ng / ml, 45 to 55 ng / ml, or 50 ng / ml.
[0086] Basic Fibroblast Growth Factor (bFGF) is a protein belonging to the FGF family that functions as a cell proliferation and differentiation factor, as well as a division-promoting factor, angiogenesis factor, bone formation factor, and nerve growth factor. Also known as FGF2, bFGF primarily activates receptor proteins including FGFR1b, FGFR1c, FGFR2c, FGFR3c, and FGFR4c, and particularly potently activates FGFR1c and FGFR3c.
[0087] Basic fibroblast growth factor is included in a concentration that allows for the proper culture of pluripotent stem cells together with other components. Basic fibroblast growth factor may be included in the fourth medium at a concentration of, for example, 1 to 40 ng / ml, 5 to 35 ng / ml, 10 to 30 ng / ml, 15 to 25 ng / ml, or 20 ng / ml.
[0088] Medium 4 may not contain a transforming growth factor beta (TGFβ) signaling inhibitor. If Medium 4 contains a TGFβ signaling inhibitor, differentiation may occur before sufficient cell proliferation has taken place.
[0089] Medium 5 is a growth medium. Like Medium 4, it contains at least growth factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF). Medium 5 may further contain other growth factors for culturing pluripotent stem cells.
[0090] The provisions regarding vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in the 5th medium shall be in accordance with the provisions regarding vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in the 4th medium.
[0091] Medium 5 contains a transforming growth factor beta (TGFβ) signaling inhibitor.
[0092] Transforming growth factor beta (TGFβ) signaling inhibitors refer to substances that inhibit TGFβ signaling. TGFβ is a substance that regulates various physiological processes in vivo, including cell proliferation, differentiation, apoptosis, migration, extracellular matrix (ECM) production, angiogenesis, and development.
[0093] TGFβ signaling inhibitors may be used without restriction as long as they are substances capable of inhibiting TGFβ signaling, for example, they may be Activin Receptor-like Kinase (ALK) receptor inhibitors.
[0094] Activin receptor-like kinase receptor inhibitors may be, but are not limited to, ALK5, ALK4, and ALK7 receptor inhibitors. For example, an ALK receptor inhibitor may be SB431542. SB431542 may be represented by the following compound name: 4-[4-(2H-1,3-benzodioxol-5-yl)-5-(pyridine-2-yl)-1H-imidazole-2-yl]benzamide.
[0095] Transforming growth factor beta (TGFβ) signaling inhibitors are included at a concentration that allows pluripotent stem cells to be cultured together with other components. Transforming growth factor beta (TGFβ) signaling inhibitors may be included at a concentration of, for example, 1 to 20 μM, 5 to 15 μM, or 10 μM.
[0096] (S1) The culture medium obtained through the culture of step (S1) contains hematopoietic stem cells (HSC). The culture medium may further contain hematopoietic progenitor cells (HPC) and megakaryocyte progenitor cells (MK-P).
[0097]
[0098] (S2) Step
[0099] Step (S2) involves cells expressing CD34 among the cells included in the culture medium of (S1) (CD34 + This is a step of obtaining a suspension cell population from the culture medium when the number of cells is at least 90% of the total number of cells.
[0100] A suspension cell population refers to cells and / or a population of cells suspended within a culture medium. Suspension cell populations contain a large number of cells capable of differentiating into megakaryocytes, such as hematopoietic stem cells, hematopoietic progenitor cells, and megakaryocytes; they may also contain cells that, while not directly differentiating into megakaryocytes, help hematopoietic stem cells, hematopoietic progenitor cells, and megakaryocytes differentiate more effectively than when they are present alone.
[0101] This step determines the optimal time to obtain a suspension cell population from the culture medium of (S1). By obtaining an optimal suspension cell population for differentiation into megakaryocytes through this step, the efficiency of differentiation into megakaryocytes and / or mature megakaryocytes and the efficiency of platelet production can be increased.
[0102] The point in time to obtain the floating cell population is CD34 + It is when the number of cells is at least 90% of the total number of cells. That is, cells that do not express CD34 (CD34 - The number of cells is less than 10% at most. CD34 + When the number of cells is 90% or more, the differentiation efficiency into megakaryocytes and platelet production efficiency are excellent.
[0103] CD34 + The number of cells is, for example, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more of the total number of cells.
[0104] The timing for obtaining the suspension cell population can be determined by considering the number of cells expressing CD41a, along with whether the cells in the culture medium express CD34.
[0105] CD41a + A suspension cell population can be obtained from the culture medium when the number of cells is, for example, 50% or more, 51% or more, 52% or more, 53% or more, 54% or more, 55% or more, 56% or more, 57% or more, 58% or more, 59% or more, 60% or more, 61% or more, 62% or more, 63% or more, 64% or more, 65% or more, 66% or more, 67% or more, 68% or more, 69% or more, 70% or more, 71% or more, 72% or more, 73% or more, 74% or more, 75% or more, 76% or more, 77% or more, 78% or more, or 79% or more of the total number of cells.
[0106] CD41a +A suspension cell population can be obtained from the culture medium when the number of cells is, for example, 80% or less, 79% or less, 78% or less, 77% or less, 76% or less, 75% or less, 74% or less, 73% or less, 72% or less, 71% or less, 70% or less, 69% or less, 68% or less, 67% or less, 66% or less, 65% or less, 64% or less, 63% or less, 62% or less, 61% or less, 60% or less, 59% or less, 58% or less, 57% or less, 56% or less, 55% or less, 54% or less, 53% or less, 52% or less, or 51% or less of the total number of cells.
[0107] In addition, the timing for obtaining the suspension cell population can be determined by considering the number of cells expressing CD42b, along with whether the cells in the culture medium express CD34.
[0108] CD42b + A suspension cell population can be obtained from the culture medium when the number of cells is, for example, 40% or more, 41% or more, 42% or more, 43% or more, 44% or more, 45% or more, 46% or more, 47% or more, 48% or more, 49% or more, 50% or more, 51% or more, 52% or more, 53% or more, 54% or more, 55% or more, 56% or more, 57% or more, 58% or more, or 59% or more of the total number of cells.
[0109] CD42b + A suspension cell population can be obtained from the culture medium when the number of cells is, for example, 60% or less, 59% or less, 58% or less, 57% or less, 56% or less, 55% or less, 54% or less, 53% or less, 52% or less, 51% or less, 50% or less, 49% or less, 48% or less, 47% or less, 46% or less, 45% or less, 44% or less, 43% or less, 42% or less, or 41% or less of the total number of cells.
[0110] In one embodiment, among the cells contained in the culture medium, CD34 +The cell count is at least 90% of the total cell count, and CD41a + A suspension cell population can be obtained from the culture medium when the number of cells is 50% to 80% of the total number of cells.
[0111] In one embodiment, among the cells contained in the culture medium, CD34 + The cell count is at least 90% of the total cell count, and CD42b + A suspension cell population can be obtained from the culture medium when the number of cells is 40% to 60% of the total number of cells.
[0112] By confirming whether the cells in the culture medium express CD34, and additionally CD41a and / or CD42b, there is no need to separately isolate or purify only the cells with the potential to differentiate into megakaryocytes from the entire cell population.
[0113] Methods for counting the number of cells may utilize conventional techniques in the industry without limitation. For example, antibody-based sorting methods or sorter machines may be used. Antibody-based sorting methods may, for example, utilize micro beads.
[0114]
[0115] (S2.5) Step
[0116] The manufacturing method of the present invention may further include the step of freezing and then thawing the suspension cell population obtained in step (S2).
[0117] Cryopreservation refers to the long-term storage of a suspension cell population in a cryogenic state (-80°C or liquid nitrogen -196°C, etc.). A suspension cell population can be placed in a cryoprotective composition and cooled slowly (e.g., at a rate of about -1°C / min) so that the suspension cells are preserved without damage and their metabolic activity is stopped.
[0118] The cryoprotective composition may include cryoprotective agents such as DMSO and glycerol.
[0119] The floating cell population contains megakaryocytes. Temporal synchronization of megakaryocytes is possible through cryopreservation. Based on the temporal synchronization of megakaryocytes, high-quality platelets can be produced with high efficiency through step (S3) described below.
[0120] Cryopreserved floating cell populations can be stored in a cell bank.
[0121] Cryopreserved suspension cell populations can be thawed. Thawing refers to the process of converting a suspension cell population, for example, stored in a liquid nitrogen tank (-196°C, gas phase / liquid phase), from a frozen state to a liquid state.
[0122] In one embodiment, a frozen suspension of cells can be transferred to a 37°C water bath or the like to be rapidly thawed so that it can be made culturable again.
[0123]
[0124] (S3) Step
[0125] Step (S3) is the step of differentiating the suspension cell population obtained in Step (S2) into megakaryocytes in the first medium.
[0126] The first medium plays the role of differentiating the floating cell population into megakaryocytes.
[0127] The first medium may include additives, such as cytokines, growth factors, signaling pathway inhibitors, or antioxidants. The first medium may include one or more selected from the group consisting of TPO, SCF, FLT-3L, SR1, and AA2P. Depending on the type of additive included in the first medium, differentiation of megakaryocytes in the first medium may be further promoted, and the quality of the platelets produced accordingly may be improved.
[0128] In one embodiment, the first medium includes a basic medium, TPO, and SCF.
[0129] In one embodiment, the first medium may further include SR1 and AA2P, thereby promoting the growth and differentiation of megakaryocytes while improving the quality of the platelets produced.
[0130] In one embodiment, the first medium does not contain interleukins. Interleukins include interleukin-3 (IL-3) and interleukin-6 (IL-6).
[0131] In one embodiment, the platelet production method of the present invention can efficiently differentiate a floating cell population into megakaryocytes using a first medium that does not contain interleukin-3 and interleukin-6.
[0132] In one embodiment, the platelet production method of the present invention may increase the expression ratio of CD41a and CD42b by using a first medium that does not contain interleukin-3 and interleukin-6, compared to when a floating cell population or megakaryocytes are cultured in a medium containing the corresponding cytokines. Accordingly, the differentiation of floating cells into megakaryocytes may be promoted more effectively.
[0133] Thrombopoietin is a major growth factor that regulates megakaryocyte and platelet hematopoiesis, and is mainly synthesized and secreted by hepatocytes.
[0134] Thrombopoietin may be included in the first medium at a concentration that allows the suspension cell population to be cultured together with other components, and it does not have to be included at a specific concentration. Thrombopoietin may be included at a concentration of, for example, 1 to 100 ng / ml, 5 to 90 ng / ml, 10 to 80 ng / ml, 20 to 70 ng / ml, or 30 to 60 ng / ml.
[0135] Stem cell factor (SCF) is a stromal cell-derived cytokine synthesized by fibroblasts and other cell types. Stem cell factor may be included in the first medium at a concentration that allows the suspension cell population to be cultured together with other components, and it does not have to be included at a specific concentration. Stem cell factor may be included at a concentration of, for example, 1 to 100 ng / ml, 5 to 90 ng / ml, 10 to 80 ng / ml, 20 to 70 ng / ml, or 30 to 60 ng / ml.
[0136] The first medium is not limited to a specific medium. The first medium may include IMDM (Iscove's Modified Dulbecco's Medium) or a conventional medium used for megakaryocyte differentiation as the basal medium. As the basal medium, serum-containing media, serum-free media, non-animal (synthetic) media, animal media, or multi-component media may be used. The basal medium may further include cytokines, growth factors, signaling pathway inhibitors, or antioxidants.
[0137] In one embodiment, the first medium may be a medium mixed with a CHO cell culture medium and an HSC proliferation medium. For example, the CHO cell culture medium and the HSC proliferation medium may be mixed in a volume ratio of 10:1 to 1:10.
[0138] In one embodiment, the first medium may further include SR1 and AA2P, thereby promoting the growth and differentiation of megakaryocytes while improving the quality of the platelets produced.
[0139] If the suspension cell population obtained in step (S2) undergoes cryopreservation and thawing steps according to step (S2.5), the thawed suspension cell population (S3') can differentiate into megakaryocytes in the first medium. Since the suspension cell population maintains the same characteristics despite cryopreservation and thawing, it can differentiate into megakaryocytes in the first medium just like the suspension cell population that did not undergo step (S2.5).
[0140] The megakaryocyte obtained in this step may have a polyploid number of chromosomes. The megakaryocyte may be tetraploid (4n), octaploid (8n), hexaploid (16n), thirtopaploid (32n), sixtopaploid (64n), or twelfthopaploid (128n).
[0141] Polyploid megakaryocytes are advantageous for mass production of platelets because they are rich in cytoplasm and can synthesize large amounts of proteins and membrane components.
[0142]
[0143] (S4) Step
[0144] Step (S4) is the step of maturing the megakaryocytes of (S3) by culturing them in a second medium containing TPO and SCF.
[0145] Thrombopoietin (TPO) may be included in the second medium at concentrations of, for example, 100 to 300 ng / ml, 110 to 290 ng / ml, 120 to 280 ng / ml, 130 to 270 ng / ml, 140 to 260 ng / ml, 150 to 250 ng / ml, 160 to 240 ng / ml, 170 to 230 ng / ml, 180 to 220 ng / ml, 190 to 210 ng / ml, or 200 ng / ml, but is not limited thereto.
[0146] Stem cell factor (SCF) may be included in the second medium at concentrations of, for example, 10 to 100 ng / ml, 20 to 90 ng / ml, 30 to 80 ng / ml, 30 to 70 ng / ml, 40 to 60 ng / ml, or 50 ng / ml, but is not limited thereto.
[0147] The second medium may contain additional factors necessary for maturing megakaryocytes.
[0148] In one embodiment, the second medium may further include heparin sodium. Heparin sodium may be included in an amount of 15 to 35 unit / ml, for example, 15 to 35 unit / ml, 16 to 34 unit / ml, 17 to 33 unit / ml, 18 to 32 unit / ml, 19 to 31 unit / ml, 20 to 30 unit / ml, 21 to 29 unit / ml, 22 to 28 unit / ml, 23 to 27 unit / ml, or 24 to 26 unit / ml.
[0149] In one embodiment, the second medium may further include a ROCK inhibitor. The ROCK inhibitor may be any one selected from the group consisting of Y-27632, Y-39983, Thiazovivin, and HA-1077.
[0150] In one embodiment, the ROCK inhibitor may be included in an amount of 0.5 to 3 μM, 0.5 to 2.8 μM, 0.5 to 2.6 μM, 0.5 to 2.4 μM, 0.5 to 2.2 μM, 0.5 to 2 μM, 0.5 to 1.8 μM, 0.5 to 1.6 μM, 0.5 to 1.5 μM, 0.5 to 1.4 μM, 0.5 to 1.3 μM, 0.5 to 1.2 μM, or 0.5 to 1.1 μM.
[0151] The second medium is not limited to a specific medium. The second medium may include IMDM (Iscove's Modified Dulbecco's Medium) medium as the basal medium. The IMDM medium may further include an antioxidant (e.g., Ascorbic Acid 2-Phosphate, AA2P, etc.), SR1 and / or B-27.
[0152] In one embodiment, megakaryocytes may be cultured in a general culture vessel or bioreactor while being stirred. In one embodiment, the stirring speed in the culture vessel or bioreactor may be 20 rpm to 300 rpm, 50 rpm to 250 rpm, 50 rpm to 250 rpm, or 100 to 200 rpm.
[0153] In one embodiment, megakaryocytes can be cultured in a culture vessel or bioreactor having baffles formed on the bottom surface.
[0154] A baffle is a protruding structure fixed to the inner wall (bottom, side, etc.) of a culture medium. Megakaryocytes can be promoted to mature and release platelets by receiving appropriate shear stress from baffles formed in a culture medium or bioreactor.
[0155] Baffles can perform functions such as inhibiting vortex formation during stirring in the culture medium, increasing the mixing efficiency of the culture medium, maintaining a uniform distribution of oxygen and nutrients, and preventing cells from settling or clumping in specific locations.
[0156] In one embodiment, the baffle is installed on the bottom surface of an incubator or bioreactor. It may be structurally installed in the incubator or bioreactor, or the baffle structure may be additionally installed in a standard incubator or bioreactor.
[0157] In one embodiment, the stirring speed in a culture vessel (such as a triangular flask) or bioreactor having baffles formed therein may be 20 rpm to 200 rpm, 50 rpm to 200 rpm, 50 rpm to 150 rpm, or 100 to 150 rpm.
[0158] In one embodiment, the megakaryocyte is 1.0 × 10 5 Up to 2×10 5 cells / cm 2 It can be administered to promote maturation and platelet release.
[0159] What is obtained in this step may be mature megakaryocytes, or a culture medium containing megakaryocytes and / or mature megakaryocytes.
[0160] The (mature) megakaryocyte obtained at this stage may have a polyploid number of chromosomes. The (mature) megakaryocyte may be tetraploid (4n), octaploid (8n), hexaploid (16n), thirtopaploid (32n), sixtopaploid (64n), or twelfthopaploid (128n).
[0161] Polyploid (mature) megakaryocytes are rich in cytoplasm and can synthesize large amounts of proteins and membrane components, which is advantageous for mass production of platelets.
[0162]
[0163] (S5) Step
[0164] Step (S5) is the step of obtaining platelets from the culture medium obtained in (S4).
[0165] This step may involve further differentiating the culture medium of (S4) and then isolating and / or purifying platelets from the culture medium, or isolating and / or purifying platelets from the culture medium without further differentiating the culture medium of (S4).
[0166] The separation and / or purification of platelets may be performed by known separation and / or purification methods. For example, it may be performed by centrifuging the culture medium or passing the culture medium through a column.
[0167] When the culture medium is centrifuged, megakaryocytes may be separated as a precipitate and platelets as a suspended solid.
[0168] (S6) Step
[0169] Step (S6) is the step of crushing the platelets obtained in Step (S5).
[0170] This step involves dissolving and destroying the obtained platelets, and the platelets may be dissolved by freezing and thawing, or by physical or chemical treatment.
[0171] The lysis of platelets can be performed by known methods. For example, platelets can be lysed by repeating the process of freezing at -20°C to -100°C and then thawing one or more times, or by using sonication, mechanical stirring, or changes in osmotic pressure.
[0172] The above-mentioned lysed platelet solution can be centrifuged to remove cell debris, and the supernatant can be recovered after centrifugation to obtain a platelet lysate.
[0173] The platelets and platelet lysates obtained according to the above method have a high content of growth factors. The platelets and platelet lysates obtained according to the method of the present invention contain not only growth factors secreted from natural platelets, but also various growth factors and cytokines involved in cell proliferation, angiogenesis, tissue regeneration, etc., at generally high levels.
[0174] The platelet lysate of the present invention has a significantly higher content of BDNF, PDGF-AA, bFGF, EGF, GDF-15, IGFBP-2, SCF R, PDGF-BB, IL-8, MCSF, or TIMP-1 compared to human blood-derived platelet lysate.
[0175] The present invention provides an artificial platelet lysate having an increased concentration of any one growth factor selected from the group consisting of BDNF, PDGF-AA, bFGF, EGF, GDF-15, IGFBP-2, SCF R, PDGF-BB, IL-8, MCSF, and TIMP-1 compared to a human-derived platelet lysate.
[0176] Human-derived platelets, or human blood-derived platelets, refer to natural platelets obtained from human blood. They refer to platelets separated and purified from whole blood or platelet concentrate collected from a healthy donor.
[0177] In one embodiment, the human-derived platelet, or human blood-derived platelet, is a normal platelet without special manipulation or pathological abnormalities.
[0178] In one embodiment, human-derived platelets, or human blood-derived platelets, may have platelet characteristics within a clinically normal range.
[0179] The artificial platelet lysate of the present invention comprises various growth factors, and includes at least one selected from the group consisting of, for example, BDNF, PDGF-AA, bFGF, EGF, GDF-15, IGFBP-2, SCF-R, PDGF-BB, IL-8, MCSF, IGFBP-2, and TIMP-1.
[0180] The artificial platelet lysate of the present invention may contain bFGF at a concentration of 0.1 to 0.3 ng / ml. The bFGF may be contained in the artificial platelet lysate at, for example, 0.10 to 0.30 ng / ml, 0.11 to 0.30 ng / ml, 0.12 to 0.30 ng / ml, 0.13 to 0.30 ng / ml, 0.14 to 0.30 ng / ml, 0.15 to 0.30 ng / ml, 0.16 to 0.30 ng / ml, 0.17 to 0.30 ng / ml, 0.18 to 0.30 ng / ml, 0.19 to 0.30 ng / ml, or 0.20 to 0.30 ng / ml.
[0181] The artificial platelet lysate of the present invention may contain bFGF in an amount of about 20 to about 40 times that of human-derived platelet lysate.
[0182] The artificial platelet lysate of the present invention may contain SCF-R at a concentration of 1 to 5 ng / ml. SCF-R may be contained in the artificial platelet lysate at, for example, 1 to 5 ng / ml, 1.5 to 5 ng / ml, 1.5 to 4.5 ng / ml, 2 to 4.5 ng / ml, 2 to 4 ng / ml, 2.5 to 4 ng / ml, or 3 to 4 ng / ml.
[0183] The artificial platelet lysate of the present invention may contain SCF-R in an amount of about 2 to about 8 times that of human-derived platelet lysate.
[0184] The artificial platelet lysate of the present invention may contain PDGF-AA at a concentration of 1 to 3 ng / ml. PDGF-AA may be contained in the artificial platelet lysate at, for example, 1.0 to 3.0 ng / ml, 1.0 to 2.8 ng / ml, 1.0 to 2.6 ng / ml, 1.0 to 2.4 ng / ml, 1.0 to 2.2 ng / ml, 1.0 to 2.0 ng / ml, or 1.0 to 1.8 ng / ml.
[0185] The artificial platelet lysate of the present invention may contain about 2 to 7 times more PDGF-AA than human-derived platelet lysate.
[0186] The artificial platelet lysate of the present invention may contain EGF at a concentration of 10 to 20 pg / ml. EGF may be contained in the artificial platelet lysate at, for example, 10 to 20 pg / ml, 11 to 19 pg / ml, 12 to 18 pg / ml, 13 to 17 pg / ml, or 14 to 16 pg / ml.
[0187] The artificial platelet lysate of the present invention may contain about 2 to 5 times more EGF than human-derived platelet lysate.
[0188] The artificial platelet lysate of the present invention may contain GDF-15 at a concentration of 0.1 to 0.2 ng / ml. GDF-15 may be contained in the artificial platelet lysate at, for example, 0.10 to 0.20 ng / ml, 0.11 to 0.19 ng / ml, 0.12 to 0.18 ng / ml, 0.13 to 0.17 ng / ml, 0.13 to 0.16 ng / ml, or 0.13 to 0.15 ng / ml.
[0189] The artificial platelet lysate of the present invention may contain about 2 to 5 times more GDF-15 than human-derived platelet lysate.
[0190] The artificial platelet lysate of the present invention may contain IGFBP-2 at a concentration of 10 to 40 ng / ml. IGFBP-2 may be contained in the artificial platelet lysate at, for example, 10 to 40 ng / ml, 15 to 40 ng / ml, 15 to 35 ng / ml, 20 to 35 ng / ml, or 25 to 35 ng / ml.
[0191] The artificial platelet lysate of the present invention may contain about 2 to 5 times more IGFBP-2 than human-derived platelet lysate.
[0192] The artificial platelet lysate of the present invention may contain PDGF-BB at a concentration of 0.5 to 1 ng / ml. PDGF-BB may be contained in the artificial platelet lysate at, for example, 0.5 to 1 ng / ml, 0.6 to 1 ng / ml, 0.6 to 0.9 ng / ml, or 0.6 to 0.8 ng / ml.
[0193] The artificial platelet lysate of the present invention may contain about 2 to 3 times more PDGF-BB compared to human-derived platelet lysate.
[0194] The artificial platelet lysate of the present invention may contain TIMP-1 at a concentration of 25 to 45 ng / ml. TIMP-1 may be contained in the artificial platelet lysate at, for example, 25 to 45 ng / ml, 22 to 42 ng / ml, 25 to 40 ng / ml, or 30 to 40 ng / ml.
[0195] The artificial platelet lysate of the present invention may contain about 1.5 to 2.5 times more TIMP-1 compared to human-derived platelet lysate.
[0196] The artificial platelet lysate of the present invention may contain BDNF at a concentration of 0.1 to 0.3 ng / ml. The BDNF may be contained in the artificial platelet lysate at, for example, 0.10 to 0.30 ng / ml, 0.11 to 0.30 ng / ml, 0.12 to 0.30 ng / ml, 0.13 to 0.30 ng / ml, 0.14 to 0.30 ng / ml, 0.15 to 0.30 ng / ml, 0.16 to 0.30 ng / ml, 0.17 to 0.30 ng / ml, 0.18 to 0.30 ng / ml, 0.19 to 0.30 ng / ml, or 0.20 to 0.30 ng / ml.
[0197] The artificial platelet lysate of the present invention may contain BDNF in an amount of about 2 to about 6 times that of human-derived platelet lysate.
[0198] In one embodiment, the artificial platelet of the present invention may be manufactured according to the manufacturing method described above.
[0199]
[0200] In addition, the present invention provides a culture medium composition comprising the aforementioned artificial platelet lysate.
[0201] In this specification, the term “medium composition” refers to a composition used to maintain or promote the survival, growth, or proliferation of cells. The medium composition may be used as the medium itself, as well as in the form of a supplement or additive added to a basic medium or a commercial medium. Additionally, the medium composition may be used in combination with other medium components or additives that aid in the growth and proliferation of cells.
[0202] The culture medium composition of the present invention can be used for the culture of various cells, specifically for the culture of immune cells, stem cells, or stromal cells.
[0203] In one embodiment, the culture medium composition of the present invention can be used for the culture of immune cells.
[0204] In one embodiment, the culture medium composition of the present invention can be used for the culture of stem cells.
[0205] In one embodiment, the culture medium composition of the present invention can be used for the culture of substrate cells for the production of cultured meat.
[0206] The immune cells of the present invention may refer, for example, T cells, B cells, natural killer cells, dendritic cells, macrophages, or monocytes.
[0207] The stem cells of the present invention may refer, for example, induced pluripotent stem cells, mesenchymal stem cells, or hematopoietic stem cells, and the stem cells of the present invention may be in the form of a single cell or an organoid.
[0208] The stromal cells of the present invention may refer, for example, to human endometrial stromal cells or human skin fibroblasts.
[0209] The culture medium composition of the present invention can be used for the culture of various cells in addition to the aforementioned cells, where the promotion of cell growth and proliferation or the maintenance of a stable culture environment is required. The culture medium composition of the present invention can be used for the culture of cells whose proliferation is promoted by growth factors.
[0210] The culture medium composition of the present invention can effectively promote cell growth and proliferation by including the artificial platelet lysate containing various growth factors at high concentrations.
[0211] The above-mentioned culture medium composition may be used alone or in combination with a basic culture medium composition. When used in combination with the basic culture medium composition, cell growth can be further promoted compared to using only the other culture medium composition.
[0212] The basic medium composition is a medium containing the minimum nutritional components necessary for the survival and proliferation of cells, and may be a medium containing amino acids, vitamins, inorganic salts, and carbon sources, and may be a medium commonly used for cell culture in the industry. The basic medium composition may be one or more selected from the group consisting of, for example, DMEM (Dulbecco's Modified Eagle's Medium), MEM (Minimal Essential Medium), BME (Basal Medium Eagle), RPMI 1640, F-10, F-12, α-MEM, Glasgow's MEM, or IMDM (Iscove's Modified Dulbecco's Medium), but is not limited thereto.
[0213] The culture medium composition of the present invention may further include any one additive selected from the group consisting of serum, insulin-transferrin-selenium supplements, glucocorticoid hormones and plant-derived protein hydrolysates.
[0214] The above serum may be, for example, fetal bovine serum (FBS), calf serum, or human serum.
[0215] The above glucocorticoid hormone may be one or more selected from the group consisting of, for example, hydrocortisone, dexamethasone, prednisolone, corticosterone, methylprednisolone, and betamethasone.
[0216] The above-mentioned plant-derived protein hydrolysate may refer to a plant-derived protein that has been broken down into low-molecular-weight peptides and amino acids through enzymatic hydrolysis or fermentation. For example, the above-mentioned plant-derived protein hydrolysate may be a protein hydrolysate produced by fermenting or enzymatically breaking down soybean protein.
[0217] The culture medium composition of the present invention may contain the artificial platelet lysate at a concentration of 1 μg / mL to 1000 μg / mL. The concentration may be appropriately selected depending on the type of cell, culture conditions, and the composition of the culture medium. If the concentration of the artificial platelet lysate is excessively high, it may cause toxicity to the cells during long-term culture, and if the concentration is excessively low, cell growth may not be sufficiently promoted.
[0218] Specifically, when the medium composition of the present invention is used together with a basic medium, the artificial platelet lysate may be included at a concentration of 1 μg / mL to 500 μg / mL, for example, 1 μg / mL to 500 μg / mL, 1 to 400 μg / mL, 10 to 400 μg / mL, 50 μg / mL to 400 μg / mL, or 100 to 400 μg / mL.
[0219] In addition, when the artificial platelet lysate is used in combination with other culture medium additives, it may be used at a concentration of 1 μg / mL to 100 μg / mL, for example, at a concentration of 1 μg / mL to 100 μg / mL, 1 to 50 μg / mL, 1 to 30 μg / mL, or 1 to 20 μg / mL. However, the concentration range may be appropriately adjusted depending on the type and concentration of the additive, the type of cell, culture conditions, etc., and is not limited thereto.
[0220]
[0221] In addition, the present invention provides a composition for promoting skin regeneration comprising the aforementioned artificial platelet lysate.
[0222] In this specification, the term “composition for promoting skin regeneration” may refer to a composition that can help improve skin conditions deteriorated due to external environments, aging, dryness, irritation, exposure to ultraviolet rays, or daily skin damage, and help restore skin, elasticity, and maintain a healthy skin condition by promoting the proliferation and activity of skin cells.
[0223] In one embodiment, the skin regeneration promoting composition may exhibit an effect of promoting the proliferation or growth of skin cells, or an effect of promoting the recovery or regeneration of cells in a skin damage model.
[0224] The composition of the present invention can exhibit effects such as promoting cell proliferation or promoting the recovery of damaged cells, and can contribute to improving the condition of the skin through these effects.
[0225] The above-mentioned skin regeneration-promoting composition can be commercialized or formulated into various forms, such as cosmetic compositions, pharmaceutical compositions, or medical devices.
[0226] When the above skin regeneration-promoting composition is formulated into a cosmetic composition, the composition may be provided in the form of a cream, lotion, essence, gel, mask pack, ampoule, ointment, spray, or patch.
[0227] In addition, the above-mentioned skin regeneration-promoting composition may further include one or more additives used in cosmetic or pharmaceutical compositions for formulation. For example, the additives may include, but are not limited to, moisturizers, emulsifiers, thickeners, stabilizers, pH adjusters, fragrances, preservatives, surfactants, or skin conditioning agents.
[0228]
[0229] The present invention will be explained in more detail below with reference to examples.
[0230]
[0231] Examples
[0232] 1. Example 1
[0233] A. Preparation of Platelets
[0234] (1) Seeding of human induced pluripotent stem cells (S0)
[0235] Human induced pluripotent stem cells were seeded according to Fig. 1a to obtain a cell population capable of differentiating into megakaryocytes.
[0236] mTeSR plus culture medium was added to a T75 flask along with 10 µg / ml of ROCK inhibitor (Y-27632), and human induced pluripotent stem cells (hiPSCs) were placed at 5,500 cells / cm² on the bottom of the T75 flask. 2 The cells were seeded at a density of and cultured at 37°C under 5% CO2 conditions. After 24 hours of culture, the cells were washed once with PBS to remove Y-27632 and replaced with fresh mTeSR plus culture medium. Human induced pluripotent stem cells were attached to the bottom of the flask by culturing for 3 days while changing the culture medium daily. Photographs of the culture medium on day 1 and day 3 are shown in Figure 1b.
[0237]
[0238] (2) Preparation of a culture medium containing human hematopoietic stem cells (S1)
[0239] A culture medium containing human hematopoietic stem cells (hHSC) was prepared according to the process and conditions of Fig. 2a.
[0240] First, attached human induced pluripotent stem cells (hiPSCs) were cultured in medium 3 for 2 days at 37°C under 5% CO2 conditions. Medium 3 was prepared by adding 6 μM of the GSK3 inhibitor CHIR99021 to RPMI1640 basal medium (containing 300 μM AA2P and 2% B-27). The medium was changed daily.
[0241] Subsequently, the third medium was replaced with the fourth medium, and culture was continued for 3 days at 37°C under 5% CO2 conditions. The fourth medium used was RPMI1640 basic medium (containing 300 μM AA2P and 2% B-27) supplemented with 50 ng / ml VEGF and 20 ng / ml bFGF. The medium was changed daily. After 3 days of culture, the cell confluence was approximately 70%. Subsequently, the cells were cultured for an additional 4 days in the fourth medium supplemented with 10 μM SB431542 (the fifth medium) to prepare a culture medium containing human hematopoietic stem cells (hHSCs). Photographs of the culture medium on days 2, 5, and 9 are shown in Figure 2b.
[0242]
[0243] (3) Obtaining a floating cell population (S2)
[0244] On the 9th day from the start of culture, the ratio of cells expressing specific surface markers (CD34, CD41a, CD42, and CD45) to the total number of suspension cells was determined through flow cytometry.
[0245] Flow cytometry analysis is BD's BD FACSLyric TM The analysis was performed using a flow cytometer. Anti-CD34-APC, anti-CD41a-FITC, anti-CD42b-PE, and anti-CD45-PE-Cy7 antibodies provided by BD were used for the analysis. Each antibody was incubated for 30 minutes in PBS (FACS buffer) containing 1% BSA, after which the expression of cell surface markers was confirmed. Through this, the proportion of cells expressing CD34 and CD45, and CD41a and CD42b alone or simultaneously, was measured, respectively.
[0246] As a result, CD34 relative to total cells + It was confirmed that the cell ratio was 97.36%, and at this point, a floating cell population was obtained from the culture medium (Fig. 3).
[0247] The proportion of cells expressing each surface marker in the obtained suspension cell population was as follows: CD45 + 58.22%; CD41a + 62.36%; and CD42b + 59.54%.
[0248]
[0249] (4) Differentiation into megakaryocytes and maturation (S3 and S4)
[0250] As shown in Fig. 4, the floating cell population is 1×10 5 They were added to the first medium at a density of 1 / ml and cultured at 37°C and 5% CO2 for 4 days to differentiate into megakaryocytes (S3).
[0251] Subsequently, the T75 flask was replaced with an Erlenmeyer flask having a baffle on the bottom, and the medium was changed from Medium 1 to Medium 2. In the changed Erlenmeyer flask, the initial megakaryocyte seeding concentration was 1.5 × 10⁶ 5 Megakaryocytes were matured by setting the cell / mL level and stirring at 120 rpm for 6 additional days at 37℃ and 5% CO2 (S4).
[0252] For the first medium, 50 ng / ml of TPO and 50 ng / ml of SCF were added to the commercial IMDM basic medium, and for the second medium, 50 ng / ml of TPO, 50 ng / ml of SCF, 25 unit / ml of heparin sodium and 1 μM of ROCK inhibitor (Y39983) were added to the IMDM basic medium with 15% FBS.
[0253]
[0254] (5) Platelet acquisition (S5)
[0255] The cell culture medium was collected and centrifuged at 300 xg for 3 minutes. The precipitate was separated into megakaryocytes, and the suspended matter into platelets. The platelets of the present invention were obtained from the suspended matter.
[0256] The platelet purification process of this embodiment is as shown in FIG. 12.
[0257]
[0258] (6) Crushing of platelets and obtaining of platelet lysate (S6)
[0259] The obtained platelets were suspended in PBS and lysed by repeating the process of freezing at -80°C for at least 20 minutes and thawing at least three times. Afterward, centrifugation was performed to remove cell debris, and platelet lysate was obtained from the supernatant.
[0260]
[0261] B. Evaluation of megakaryocytes
[0262] The results of the analysis of surface markers of megakaryocytes obtained in step (S3) are shown in Table 1 below. Surface marker analysis was performed using the method described above.
[0263] (S3) Megakaryocyte surface marker cell ratio (%) CD41a + CD42b + CD45 + Example 189.3388.7536.77
[0264] Megakaryocytes from step (S3) were fixed in 70% ethanol at -20°C for 24 hours to perform cell membrane permeability treatment, then treated with RNase and reacted at 4°C for 30 minutes. Afterward, DNA was stained with PI (propidium iodide) staining reagent (4°C, 10 minutes), and the multinucleity (chromosome number) of the cells was analyzed using a flow cytometer. As a result of the analysis, a peak was observed in which the DNA content within the megakaryocytes increased from 2N to 16N, confirming that the chromosome number of the megakaryocytes in Example 1 increased to a maximum of 16-ploidy (Fig. 6).
[0265] The characteristics of the megakaryocytes obtained in step (S4) were analyzed. Electron microscopy of the cells confirmed structures present in megakaryocytes, such as a multilobed nucleus, alpha granules, and a demarcation membrane system (Fig. 7). When the chromosome number of mature megakaryocytes was determined using the same method, a peak was observed in which the intracellular DNA content increased from 2N to 128N, confirming the formation of high-double mature megakaryocytes (Fig. 8).
[0266]
[0267] C. Evaluation of Platelets
[0268] (1) Structural analysis of platelets
[0269] The structure of the cells obtained in step (S5) was observed using an electron microscope. The cells in step (S5) had structures present in platelets, such as microtubules, alpha granules, compact tubules, open tubular systems, and delta granules (Fig. 9).
[0270]
[0271] (2) Analysis of platelet count and surface markers
[0272] The expression of surface markers obtained from cells in step (S5) was confirmed by flow cytometry. Flow cytometry was performed using a BD FACSLyric™ Flow Cytometer, and BD's anti-CD41a-FITC, anti-CD61-PE, and anti-CD42b-APC antibodies were used. The antibodies were diluted 1:20 in PBS (FACS buffer) containing 1% BSA, reacted at room temperature for 30 minutes, and surface marker expression was confirmed.
[0273] (S5) The results of the analysis of the number of cells and their surface markers in step (S5) are as shown in Table 2 below.
[0274] Differential platelet count (x10 6 PLT / mL) Cell Ratio (%) CD41a + CD42b + CD61+ Example 19.791.392.296.2
[0275] (3) Confirmation of platelet activity
[0276] The activity of the platelets obtained in step (S5) was confirmed. Platelet activity was confirmed through the expression levels of PAC-1 and CD62P. PAC-1 is a monoclonal antibody formed by the complex of CD41 and CD61 when platelets are activated, and CD62P is a cell surface adhesion molecule whose expression increases when platelets are activated, providing a site for leukocytes to bind to platelets.
[0277] Cells were treated with 400 ng / mL of PMA and incubated at room temperature for 15 minutes, after which BD’s anti-PAC-1-FITC and anti-CD62p-PE antibodies were incubated for 30 minutes. Subsequently, flow cytometry was performed on the reacted cells.
[0278] The expression levels of PAC-1 and CD62p in the platelets obtained in step (S5) are as shown in Table 3 below.
[0279] Platelet activity (%) PAC-1CD62P Example 180.972.9
[0280] (S5) The platelets at stage had very high expression levels of PAC-1 and CD62p. This indicated that the platelets of Example 1 were high-quality platelets with excellent activity as platelets.
[0281]
[0282] D. Analysis of characteristics of the suspension cell population after freezing and thawing
[0283] (S2) It was confirmed whether high-quality platelets could be produced even after freezing and thawing the suspension cell population obtained in step (S2).
[0284] The suspension cell population obtained in step (S2) was passed through a 70 µm mesh to remove clumped adhered cells. The resulting cell culture medium was centrifuged at 500xg for 5 minutes to precipitate the cells. The supernatant was removed, and the cells were washed with a small amount of PBS and centrifuged again. Subsequently, the supernatant was removed, and the cells were placed in CS10 cryopreservation medium at a rate of 2 x 10⁶ 7 1 mL was dispensed into 1.8 mL cryovials to achieve a cell / mL ratio. The cryovials were placed in freezing containers and stored in a -70°C ultra-low temperature freezer; after 24 hours, they were transferred to a -180°C liquid nitrogen storage container for frozen storage.
[0285] Frozen cells were thawed in a 37°C water bath, a small amount of cell proliferation medium was added, and the cells were centrifuged. The precipitated cells were recirculated using cell proliferation medium and transferred to a flask for culture. Using the same method as above, the ratio of cells expressing a specific surface marker to the total number of flow cells was determined.
[0286] As a result, the floating cell population CD34 even after freezing and thawing + Cell ratio 94.30%, CD45 + Cell ratio 44.89%, CD41a + Cell ratio 57.82%, CD42b + It was confirmed that the characteristics were substantially the same as the cell ratio was maintained at 53.8% (Fig. 5).
[0287]
[0288] 2. Examples 2-4 and Comparative Examples 1-2
[0289] Seeding density of human induced pluripotent stem cells CD34 of the floating cell population + To determine the effect on the cell ratio, the seeding density of human induced pluripotent stem cells in step (S0) of Example 1 was set to 6,000 to 10,000 cells / cm² as shown in Table 1 below. 2Platelets of Examples 2-4 and Comparative Examples 1-2 were prepared by changing the method.
[0290] For the platelets of Examples 2-4 and Comparative Examples 1-2, the remaining steps (S1) to (S5) were performed in the same manner as in Example 1, except that the seeding density of human induced pluripotent stem cells in step (S0) was changed.
[0291] The ratio of cells expressing each surface marker in the suspension cell population at the 9th day from the start of culture in each (S2) step of Examples 2-4 and Comparative Examples 1-2 was as shown in Table 4 below.
[0292] Classification Example 2 Example 3 Example 4 Comparative Example 1 Comparative Example 2 Cell density (cells / cm²) 2 )6,000 7,000 8,000 9,000 10,000 (S2) Cell ratio of floating cell population (%) CD34 + 97.3393.9893.4588.6179.47CD45 + 33.2934.0827.9522.7924.17CD41a + 64.9360.7363.1960.4349.09CD42b + 53.7147.9443.5542.1628.95
[0293] Accordingly, CD34 of the floating cell population + To maintain a cell ratio of over 90%, 9,000 cells / cm² of (S0) stage human induced pluripotent stem cells 2 It was possible to see that seeding had to be done at a level below.
[0294]
[0295] 3. Examples 5-11 and Comparative Examples 3-6
[0296] To determine the effect of the composition of the first medium on differentiation ability into megakaryocytes, the composition of the first medium in step (S3) of Example 1 was changed as shown in Table 5 below, and platelets of Examples 5-11 and Comparative Examples 3-6 were prepared. The remaining processes and conditions were performed in the same manner as in Example 1.
[0297] First Medium Preliminary Comparative Example 5678910113456 Basic Medium IMDMTPO(ng / ml)505050505050505050505050SCF(ng / ml)505050505050505050505050FLT-3L(ng / ml)101010-10---101010SR1(μmol)11-1-1-1111AA2P(μmol)300-300300--300300300300-G-CSF(ng / ml)-------10-1010IL-3(ng / ml)-------1010-10IL-6(ng / ml)-------1010-10
[0298] The results of analyzing the surface markers of megakaryocytes obtained in each (S3) step of Examples 5-11 and Comparative Examples 3-6 are as shown in Table 6 below.
[0299] (S3) Megakaryocyte surface marker cell ratio (%) CD41a + CD42b + CD45 + Example 583.9282.9040.90 Example 683.0783.2339.29 Example 789.1288.3739.32 Example 883.1682.1941.69 Example 988.7087.8537.97 Example 1084.0283.6638.70 Example 1190.2889.6636.76 Comparative Example 345.4050.3075.66 Comparative Example 452.3956.6474.47 Comparative Example 563.2366.6363.35 Comparative Example 651.8755.8769.71
[0300] The examples compared to the comparative examples CD41a + and CD42b + Megakaryocytes with a high cell ratio were produced, and accordingly, it was confirmed that megakaryocytes with excellent differentiation ability into platelets were produced when the first medium of the examples was used.
[0301] Based on the surface marker analysis results for the comparative example, it is determined that the addition of G-CSF, IL3, and IL6 actually inhibits differentiation into megakaryocytes.
[0302] The number of platelets and surface markers of Examples 5-11 were analyzed using the same method as in Example 1. The results of the analysis of the number of platelets and surface markers of Examples 5-11 are shown in Table 7 below.
[0303] Differential platelet count (x10 6 PLT / mL) Cell Ratio (%) CD41a + CD42b + CD61 + Example 5 13.679.183.590 Example 69.983.486.492 Example 7 10.481.583.991.5 Example 8 12.190.491.795.5 Example 9 12.489.790.495.3 Example 10 11.590.591.895.7 Example 11 11.689.390.895.4
[0304] All platelets in Examples 5-11 were of excellent quality. It was confirmed that cell growth was promoted when FLT-3L, SR1, AA2P, etc. were additionally added to the first medium.
[0305]
[0306] 4. Examples 12-16
[0307] To determine the effect of the composition of the second medium on platelet production, platelets were produced by changing the density of megakaryocytes introduced into the second medium of Example 1 and the concentration of Y39983 included in the second medium as shown in Table 8 below.
[0308] Classification Example 1 2 1 3 1 4 1 5 1 6 Megakaryocyte input density (cell / mL) 1.5 × 10⁻⁶ 5 2.0×10 5 1.5×10 5 2.0×10 5 2.0×10 5 Y39983(μmol)0.51235
[0309] The results of analyzing the number of platelets, surface markers, and their cellular activity in Examples 12-16 are as shown in Table 9 below.
[0310] Differential platelet count (x10 6PLT / mL) Cell Ratio (%) Cell Activity (%) CD41a + CD42b + CD61 + PAC-1 Example 1 25.091.392.296.258.0 Example 1 38.979.183.59060.3 Example 1 45.883.486.49253.9 Example 1513.290.491.795.551.7 Example 1611.990.591.895.749.6
[0311] All platelets of Examples 12-16 had abundant expression of platelet surface markers and were of excellent platelet quality.
[0312]
[0313] 5. Examples 17-22
[0314] To evaluate the effect of the type of culture vessel and stirring speed used in step (S4) on platelet production, the bottom baffle structured triangular flask used in Example 1 was replaced with a Bioreactor. Subsequently, platelets were produced by changing the stirring speed according to the conditions presented in Table 10, and mechanical stress (shear force) was applied to the cells in step (S4) by gradually increasing the stirring speed.
[0315] (S4) Stage Culture Day 0 Day 1 Day 2 Day 3 Day 4 Day 5 Example 17 250rpm Example 18 100rpm 250rpm Example 19 100rpm 250rpm Example 20 100rpm 250rpm Example 21 100rpm 150rpm Example 22 100rpm 350rpm
[0316] The results of analyzing the number of platelets and surface markers of Examples 17 to 22 are as shown in Table 11 below.
[0317] Cell Ratio (%) Cell Activity (%) CD41a+ CD42b+ CD61+ PAC-1 Example 1 791.892.983.154.7 Example 1894.795.190.757.1 Example 1993.093.786.149.3 Example 2096.696.592.963.1 Example 2183.682.292.457.3 Example 2288.880.992.258.9
[0318] The platelets of Examples 17-22 were all of excellent quality. It was confirmed that platelet production proceeded well not only in flasks but also in bioreactors.
[0319]
[0320] 6. Comparative Example 7
[0321] mTeSR plus culture medium was added to a T75 flask along with 10 µg / ml of ROCK inhibitor (Y-27632), and human induced pluripotent stem cells (hiPSCs) were placed at 4,000 cells / cm² on the bottom of the T75 flask. 2 The cells were seeded at a density of [value] and cultured under conditions of 37°C and 5% CO2. After 24 hours of culture, the cells were washed once with PBS to remove Y-27632 and replaced with fresh mTeSR plus culture medium. Human induced pluripotent stem cells were attached to the bottom of the flask by culturing for 3 days while changing the culture medium daily.
[0322] Subsequently, the attached human induced pluripotent stem cells (hiPSCs) were cultured in medium A at 37°C and 5% CO2 for 2 days. Medium A was prepared by adding 6 μM of the GSK3 inhibitor CHIR99021 to RPMI1640 basal medium (containing 300 μM AA2P and 2% B-27). The medium was changed daily.
[0323] Afterwards, medium A was replaced with medium B, and culture was continued for 3 days at 37°C and 5% CO2. Medium B was prepared by adding 50 ng / ml VEGF and 20 ng / ml bFGF to RPMI1640 basic medium (containing 300 μM AA2P and 2% B-27). The medium was replaced daily. Subsequently, culture was further conducted for 4 days in medium (medium C) to which 10 μM SB431542 was added to medium B to prepare a culture medium containing human hematopoietic stem cells (hHSC).
[0324] On the 9th day from the start of culture, the ratio of cells expressing specific surface markers (CD41a and CD45) to the total number of suspension cells was determined via flow cytometry, and CD41a relative to the total cells + It was confirmed that the cell ratio was 82.74%, and at this point, a floating cell population was obtained from the culture medium.
[0325] The proportion of cells expressing each surface marker in the obtained suspension cell population was as follows: CD45 + 8.57%; and CD34 + 77.01%.
[0326] The obtained suspension cell population is 1×10 5 The cells were introduced into medium D at a density of cells / mL and cultured at 37°C and 5% CO2 for 3 days to differentiate into megakaryocytes. Afterward, the medium D was changed to medium E and cultured for an additional 5 days at 37°C and 5% CO2 to mature the megakaryocytes.
[0327] For medium D, IMDM basic medium containing 300 µM AA2P and 2% B-27 was supplemented with 25 ng / ml TPO, 25 ng / ml SCF, 10 ng / ml IL-3, and 10 ng / ml IL-6, and for medium E, IMDM basic medium containing 300 µM AA2P and 2% B-27 was supplemented with 100 ng / ml TPO.
[0328] The cell culture medium was collected and centrifuged at 300 xg for 3 minutes. The precipitate was separated into megakaryocytes, and the suspended matter into platelets. Platelets of Comparative Example 7 were obtained from the suspended matter.
[0329]
[0330] 7. Comparative analysis of growth factors in Example 1 and human-derived platelets
[0331] The content of major growth factors contained in the platelets of Example 1 was calculated through ELISA analysis and compared with human-derived platelets.
[0332] Human-derived platelets (hbPLT) were obtained as follows. Blood was collected from a donor at the Catholic University of Korea St. Mary's Hospital with the approval of the Institutional Review Board (IRB) (Approval No. CPT 2022-01). The human blood obtained through collection was placed in a conical tube, centrifuged at 150 g for 10 minutes to separate the supernatant, and transferred to a new conical tube. Subsequently, an equal volume of Tyrode buffer containing prostaglandin E-1 (PGE-1) at a concentration of 50 ng / mL was added, and the supernatant was removed by centrifugation at 2000 g for 10 minutes. Afterward, the sample was resuspended in T-PAS buffer or Tyrode buffer and used for analysis.
[0333] ELISA kits for each growth factor were used for the quantitative analysis of PDGF-AA, PDGF-BB, EGF, TGF-β, bFGF, and VEGF. The results of the analysis, performed according to the methods provided by each manufacturer, were measured using SpectraMAX M2.
[0334] As a result, it was confirmed that artificial platelets contain a wider variety of growth factors at significantly higher concentrations compared to human blood-derived platelets (hbPLT) (Fig. 10, Table 12).
[0335] Growth factor concentration (pg / ml) Human blood-derived platelets (hbPLT) Platelets of Example 1 PDGF-AA83013,800 PDGF-BB4105,900 EGF40280 TGF-b501,100 bFGF<0.011,643 VEGF10210
[0336] As shown in Table 12, the manufactured artificial platelets contained PDGF-AA, PDGF-BB, EGF, TGF-β, bFGF, and VEGF at high concentrations ranging from at least 7 times to up to about 20 times higher than human blood-derived platelets.
[0337]
[0338] 8. Comparative analysis of growth factors in Example 1 and human blood-derived platelet lysates
[0339] The types and content of growth factors included in the platelet lysate of Example 1 were three commercially available human blood-derived platelet lysates (human platelet lysate (stem cell technology), PLTgold ® (Mill Creek), PLTgold ® It was compared with the average of (sartorius).
[0340] The platelets of Example 1 were placed in a cell lysis buffer treated with 1% each of a protease inhibitor and a phosphatase inhibitor, frozen and thawed at -80°C for at least 20 minutes, at least three times, and then the supernatant was obtained by centrifugation. The supernatant was a platelet lysate and was prepared according to method (6) of Example 1.
[0341] All samples were standardized to 1 mg / ml through quantitative analysis using a BCA protein analysis kit (Pierce). Trend analysis of various growth factors contained in each sample was performed using a Quantibody array (Raybiotech). Samples standardized to 1 mg / ml were analyzed according to the method provided by the manufacturer, and the results were analyzed using a GenePix 4100A scanner (Axon instrument). The results are shown in Table 13 and Figure 11 below.
[0342] Growth Factor Content (pg / ml) Growth Factor Content (pg / ml) Example 1 Commercial Platelet Example 1 Commercial Platelet AR3 3.4 11 5.2 BLC 0.3 0.7 BDNF 2 19.7 54.7 Eotaxin 3.0 2.4 bFGF 25 7.4 10.0 Eotaxin-2 11.5 33.1 BMP-4 22.3 41.4 G-CSF 4.9 2.1 BMP-5 16 5.0 1,266.3 GM-CSF 7 2.0 21.0 BMP-7 20 8.2 1,576.5 I-3 09 32.0 25.8 b-NGF 0.6 3.8 ICAM-11,21 0.1 3,226.8 EGF 14.9 5.1 IFNg 14.2 8.2 EGF R470.6402.0IL-1a21.311.8EG-VEGF3.034.3IL-1b8.44.4FGF-452.1282.0IL-1ra35.620.5FGF-719.3114.3IL-2959.2200.0GDF-151 43.440.3IL-412.03.0GDNF10.576.6IL-5817.7356.4GH31.9155.1IL-672.630.3HB-EGF1.56.3IL-6R243.0395.6HGF14.633.5IL-7684 .9202.2IGFBP-121.744.8IL-878.99.3IGFBP-229,656.48,429.7IL-1033.53.3IGFBP-3331.12,214.9IL-11343.5110.3IGFBP-419.62 17.8IL-12p4025.215.2IGFBP-6127.81545.6IL-12p7014.16.9IGF-I65.0211.8IL-131.00.3Insulin138.7524.9IL-1573.7104.7MCSF R33.9706.6IL-16129.7105.8NGF R61.4119.8IL-1715.75.5NT-318.5102.1MCP-14.72.6NT-459.2383.5MCSF3.30.3OPG1.48.1MIG24.8 22.6PDGF-AA1,469.4358.3MIP-1a4.07.2PIGF1.48.6MIP-1b1.00.8SCF90.257.5MIP-1d19.738.7SCF R3,869.3642.4PDGF-BB754.3448.8TGFa1.59.6RANTES4,957.45,510.3TGFb1114.1525.4TIMP-134,302.519,662.7TGFb326.2170.3TIMP-2364.78,242.1VEGF236.8124.3TNFa145.794.5VEGF R2390.3961.6TNFb327.4127.1VEGF R3122.1840.6TNF RI58.956.3VEGF-D62.9198.8TNF RII43.6180.9.
[0343] As shown in Table 13, the artificial platelet lysate of Example 1 contains more BDNF, PDGF-AA, bFGF, EGF, GDF-15, IGFBP-2, SCF R, PDGF-BB, IL-8, MCSF, and TIMP-1 compared to the human blood-derived platelet lysate.
[0344] The artificial platelet lysate of Example 1 contains bFGF, GDF-15, IGFBP-2, and SCF R at concentrations at least 3 times higher than human blood-derived platelets, and TIMP-1 at least 1.5 times higher. Accordingly, the artificial platelet lysate of the present invention is expected to have excellent angiogenesis and tissue regeneration effects.
[0345] In addition, the artificial platelet lysate of Example 1 also contains inflammatory and immunomodulatory factors such as IL-8 and MSCF at significantly increased concentrations compared to human blood-derived platelets.
[0346]
[0347] In addition, the relative intensity of various growth factors included in each sample was analyzed using the same method. The results are shown in Table 14 below.
[0348] Growth factor Relative intensity Growth factor Relative intensity Example plate Platelet Example plate PlateletsAR0.0210.028BLC0.0350.043BDNF1.9350.503Eotaxin0.0310.029bFGF0.1500.025Eotaxin-20.0340.064BMP-40.0210.024G-CSF0.0350.027 BMP-50.0220.035GM-CSF0.0460.031BMP-70.0230.039I-3090.0350.029b-NGF0.0210.033ICAM-10.0510.128EGF0.1690.061IFNg0.0440.033EGF R0.0860.082IL-1a0.0420.033EG-VEGF0.0210.050IL-1b0.0300.024FGF-40.0200.029IL-1ra0.0290.024FGF-70.0200.031IL-20.0480.031GDF- 150.1680.073IL-40.0480.035GDNF0.0200.033IL-50.0610.035GH0.0380.051IL-60.0630.045HB-EGF0.0230.033IL-6R0.0850.123HGF0.0210.02 5IL-70.0530.034IGFBP-10.0310.039IL-80.1060.042IGFBP-20.1590.058IL-100.0540.036IGFBP-30.0210.039IL-110.0370.028IGFBP-40.0210 .033IL-12p400.0370.028IGFBP-60.0190.043IL-12p700.0390.031IGF-I0.0210.029IL-130.0460.033Insulin0.0210.029IL-150.0430.054MCSF R0.0200.057IL-160.0450.041NGF R0.0190.024IL-170.0310.024NT-30.0210.032MCP-10.0490.038NT-40.0210.039MCSF0.0900.026O PG0.0200.034MIG0.0260.024PDGF-AA0.8400.340MIP-1a0.0280.036PIGF0.0210.033MIP-1b0.0420.036SCF0.0430.036MIP-1d0.0320.036SCF R0.1900.041PDGF-BB3.9942.338TGFa0.0190.036RANTES2.5162.719TGFb10.0270.050TIM P-10.7940.453TGFb30.0230.040TIMP-20.0360.341VEGF0.0350.027TNFa0.0530.048VEGF R20.0280.041TNFb0.0470.032VEGF R30.0250.044TNF RI0.0250.024VEGF-D0.0190.025TNF RII0.0270.051.
[0349] As shown in Table 14, it was confirmed that the platelet lysate of Example 1 contains many growth factors, such as PDGF-AA, PDGF-BB, bFGF, EGF, VEGF, GDF-15, IGFBP-2, SCF-R, TIMP-1, and IL-8, at significantly higher levels compared to human blood-derived platelet lysate products.
[0350]
[0351] 9. Analysis of the cell growth-promoting ability of platelet lysates
[0352] To determine whether the platelet lysate of Example 1 can promote cell growth in various cells, and FBS (fetal bovine serum) and HPL (PLTgold ® It was compared with human platelet lysate.
[0353] The ability to promote cell growth in human umbilical cord Wharton's jelly-derived mesenchymal stem cells, human endometrial stromal cells, and human T lymphocytes was confirmed through CCK-8 analysis. Alpha-MEM was used for human umbilical cord Wharton's jelly-derived mesenchymal stem cells, DMEM for human endometrial stromal cells, and IMDM for human T lymphocytes as cell culture media; however, depending on the test group, a combination of the platelet lysate of Example 1, 10% FBS, and 10% HPL was applied. The absorbance at 450 nm was measured for cells cultured under each condition. The absorbance value of cells cultured under a medium containing 10% FBS on Day 0 was set to 100%, and the absorbance values of each experimental group were converted into relative values to quantitatively compare the cell growth-promoting effect.
[0354] As a result, as shown in Figures 13a to 13c, it was confirmed that the platelet lysate of Example 1 effectively promotes cell growth in all cells. In the case of human umbilical cord Wharton's jelly-derived mesenchymal stem cells and human endometrial stromal cells, the group treated with 3% of the platelet lysate of Example 1 showed a cell growth-promoting effect equivalent to or greater than that of the groups treated with 10% FBS and 10% HPL. Furthermore, human T lymphocytes showed a cell growth effect similar to that of 10% FBS and 10% HPL in the group treated with 1.5% of the platelet lysate of Example 1, and when the concentration of the platelet lysate of Example 1 was 3%, a cell growth-promoting effect more than 2.5 times higher than that of the 1.5% treatment group was confirmed. Therefore, it was confirmed that the platelet lysate of Example 1 can effectively promote cell growth even at lower concentrations compared to commercial medium additives or commercially available platelet lysates.
[0355]
[0356] 10. Confirmation of the cell growth-promoting effect of platelet lysates in cells
[0357] It was determined whether the medium composition containing the platelet lysate of Example 1 could promote cell growth.
[0358] Human skin fibroblasts were treated with the platelet lysate of Example 1 (10 μg / ml), ITS-X (1x), FBS (2.5%), or a combination thereof as shown in FIG. 14.
[0359] Human skin fibroblasts were inoculated into T25 flask culture vessels at a density of 1×10⁴ cells / cm² and cultured for 3 days at 37°C in a 5% CO₂ environment using a medium combining 2.5% FBS, 1% ITS, and 10 μg / ml platelet lysate, depending on the test group. The growth trends of the cultured cells were observed using a microscope. Additionally, cells were harvested using Trypsin-EDTA, and the degree of cell growth was analyzed by counting the harvested cells using a cell counter.
[0360] As a result, as shown in Fig. 15, it was confirmed that artificial platelet lysate can further promote cell growth when added to a medium composition containing FBS.
[0361]
[0362] 11. Confirmation of Cell Regeneration Effects of Platelet Lysates
[0363] The cell regenerative ability and wound healing ability of the platelet lysate of Example 1 were confirmed.
[0364] Human dermal fibroblasts were inoculated into a 6-well plate at a density of 3.5 × 10⁴ cells / cm² and cultured for 24 hours at 37°C under 5% CO₂ conditions to simulate a skin environment. Subsequently, an in vitro scratch wound model was formed by inducing physical damage by scraping the surface of the cultured fibroblasts using a micropipette tip.
[0365] After inducing injury, the cell surface was washed with phosphate-buffered saline, and then treated with FBS (fetal bovine serum) and the platelet lysate of Example 1, respectively, followed by additional culture for 48 hours. After the culture was completed, the degree of recovery of the injury site was confirmed through microscopic observation, and the change in the area of the injury site was quantitatively evaluated by analyzing the change using the ImageJ program.
[0366] As a result, as shown in Figures 16 and 17, cell regeneration and recovery were significantly promoted when the platelet lysate of Example 1 was additionally treated compared to when only FBS was treated, and it was confirmed that the damaged area was recovered to a substantially 100% level.
[0367]
[0368] 12. Confirmation of the cell culture-promoting effect of platelet lysates
[0369] (1) Confirmation of cell culture promotion by adding artificial platelet lysate
[0370] The results of cell culture in a culture medium containing the platelet lysate of Example 1 were analyzed.
[0371] Human skin fibroblasts were inoculated into T25 flask culture vessels at a density of 1×10⁴ cells / cm² and cultured for 3 days at 37°C in a 5% CO₂ environment with 5 ml of medium combining FBS 2.5%, ITS 1%, Hydrocortisone 100 ng / ml, and platelet lysate of Example 1 10 μg / ml, according to each test group. The growth trends of the cultured cells were observed through microscopic examination. In addition, cells were recovered using Trypsin-EDTA, and the degree of cell growth was analyzed by counting the recovered cells using a cell counting device (Countess).
[0372] As a result, as shown in Figures 18 and 19, when the artificial platelet lysate of Example 1 was added, the growth of human skin fibroblasts was further promoted compared to when it was not added. In particular, it was confirmed that when the artificial platelet lysate of Example 1 was additionally added to a medium containing ITS or hydrocortisone in FBS, cell growth was promoted more effectively.
[0373]
[0374] (2) Confirmation of cell culture promotion effect according to medium composition control
[0375] Human skin fibroblasts were inoculated into T25 flask culture vessels at a density of 1×10⁴ cells / cm² and cultured for 3 days at 37°C in a 5% CO₂ environment with 5 ml of medium prepared according to each test group, which contained a combination of FBS 2.5%, ITS 1%, Hydrocortisone 100 ng / ml, Hypep1510 100 µg / ml, and platelet lysate 10 μg / ml. The growth trends of the cultured cells were observed through microscopic examination. Additionally, cells were harvested using Trypsin-EDTA, and the degree of cell growth was analyzed by counting the harvested cells using a cell counter.
[0376] As a result, as shown in Figures 20 and 21, when the artificial platelet lysate of Example 1 was treated alone, significant growth of human skin fibroblasts was not observed. However, it was confirmed that cell growth increased by approximately twofold when the artificial platelet lysate of Example 1 was additionally included with ITS and hydrocortisone compared to a medium containing only ITS and hydrocortisone. Furthermore, compared to a medium containing only Hypep 1510 with ITS and hydrocortisone, cell growth was promoted by more than twofold when the artificial platelet lysate of Example 1 was additionally included, and this level was confirmed to be higher than when FBS was treated alone. Therefore, it was confirmed that by using the artificial platelet lysate of the present invention, conditions for effectively culturing cells even under serum-free conditions can be established.
Claims
Artificial platelet lysate comprising 0.1 to 0.3 ng / ml bFGF, 1 to 5 ng / ml SCF-R, 1 to 3 ng / ml PDGF-AA, 10 to 20 pg / ml EGF, 0.1 to 0.2 ng / ml GDF-15, and 10 to 40 ng / ml IGFBP-2.
2. An artificial platelet lysate according to claim 1, further comprising 0.5 to 1 ng / ml of PDGF-BB and 25 to 45 ng / ml of TIMP-1.
3. In claim 1, the artificial platelet lysate comprises: (S1) a step of culturing pluripotent stem cells to obtain a culture medium containing hematopoietic stem cells; (S2) among the cells contained in the culture medium, CD34 + An artificial platelet lysate prepared by a method comprising the steps of: (S3) obtaining a suspension cell population from the culture medium when the number of cells is at least 90% of the total number of cells; (S4) differentiating the suspension cell population into megakaryocytes in a first medium; (S5) culturing and maturing the megakaryocytes in a second medium containing TPO and SCF; (S6) isolating and purifying the culture of (S4) to obtain platelets; and (S6) crushing the platelets.
4. The artificial platelet lysate according to claim 3, wherein step (S1) comprises: (S1a) culturing the pluripotent stem cells in a third medium containing a GSK3 inhibitor; (S1b) culturing the cells cultured in the third medium in a fourth medium containing vascular endothelial growth factor and basic fibroblast growth factor; and (S1c) culturing the cells cultured in the fourth medium in a fifth medium containing vascular endothelial growth factor; basic fibroblast growth factor; and a transforming growth factor beta signaling inhibitor.
5. In claim 3, the method comprises (S0) pluripotent stem cells at a density of 5,000 to 8,500 cells / cm² on the bottom of a culture vessel. 2 Artificial platelet lysate including an additional seeding step.
6. The artificial platelet lysate of claim 3, wherein the first medium comprises TPO and SCF and does not comprise interleukin-3 and interleukin-6.
7. In claim 6, among the cells included in the culture medium in (S2), CD34 + The cell count is at least 90% of the total cell count, and CD41a + The cell count is 50% to 80% of the total cell count, and CD42b + An artificial platelet lysate obtained from the culture medium when the number of cells is 40% to 60% of the total number of cells.
8. The artificial platelet lysate of claim 3, wherein the second medium further comprises heparin sodium and a ROCK inhibitor.
9. In claim 3, the megakaryocytes are 1.0 × 10⁶ in a culture vessel having baffles formed on the bottom surface, or in a stirred bioreactor. 5 Up to 2×10 5 cells / cm 2 Artificial platelet lysate that is injected and cultured.
10. A culture medium composition comprising an artificial platelet lysate according to any one of claims 1 to 9.
11. A culture medium composition according to claim 10, further comprising any one additive selected from the group consisting of serum, insulin-transferrin-selenium supplements, glucocorticoid hormones, and plant-derived protein hydrolysates.
12. A culture medium composition according to claim 11, wherein the glucocorticoid hormone is one or more selected from the group consisting of hydrocortisone, dexamethasone, prednisolone, corticosterone, methylprednisolone, and betamethasone.
13. A culture medium composition according to claim 11, wherein the plant-derived protein hydrolysate is a hydrolysate of a protein derived from any one plant selected from the group consisting of soybeans, wheat, peas, rice, potatoes, and corn.
14. A culture medium composition according to claim 10, wherein the artificial platelet lysate is included at a concentration of 1 μg / mL to 1000 μg / mL.
15. A culture medium composition used for culturing any one or more selected from the group consisting of immune cells, stem cells, and stromal cells, according to claim 10.
